Management of Syphilis with Low RPR Titers

Understanding the Clinical Context

A patient with a history of treated syphilis and a current RPR titer of 1:1 generally does not require retreatment, as this represents a serologic scar rather than active infection, according to the Centers for Disease Control and Prevention (CDC) 1, 2
An RPR titer of 1:1 in someone with prior syphilis typically indicates a persistent low-level nontreponemal antibody response following successful treatment, which occurs in approximately 15-25% of treated patients and does not indicate active infection, as reported by the CDC 1, 3

The CDC recommends not retreating a patient with a history of syphilis and an RPR titer of 1:1 if there are no clinical signs or symptoms of active syphilis, the titer has remained stable or is declining, and the patient was adequately treated previously 1, 2
Patients with HIV infection and high-risk features, such as a CD4 count ≤350 cells/mL, should be monitored more closely, although a stable 1:1 titer does not automatically require retreatment, according to the CDC 2, 4, 5
Pregnant women with an RPR titer of 1:1 require more aggressive management and should be evaluated by specialists to prevent congenital syphilis, as recommended by the CDC 6

Patients with persistently low RPR titers (1:1 to 1:4) after appropriate treatment are considered "serofast" and do not require additional therapy in the absence of clinical findings, according to the CDC 1, 3
HIV-infected patients may have atypical serologic responses, but standard treatment regimens remain appropriate, as reported by the CDC 2, 4, 5

For a patient with an RPR titer of 1:1 and no concerning features, the CDC recommends performing a clinical examination to exclude signs of active syphilis, reviewing the trend of previous RPR titers, and reassuring the patient that low-level persistent antibodies are expected and do not indicate active infection 1, 2
The CDC also recommends repeating RPR testing only if new symptoms develop or new sexual exposure occurs, and ensuring HIV testing has been performed, as all syphilis patients should be tested for HIV 1, 2, 3

The Centers for Disease Control and Prevention recommends a single dose of benzathine penicillin G 2.4 million units IM for primary and secondary syphilis 7, 8
For early latent syphilis, the recommended treatment is a single dose of benzathine penicillin G 2.4 million units IM 7, 8
For late latent syphilis or unknown duration, the treatment is benzathine penicillin G 2.4 million units IM weekly for 3 weeks (total 7.2 million units) 7, 9
For neurosyphilis, the recommended treatment is aqueous crystalline penicillin G 18-24 million units per day, administered as 3-4 million units IV every 4 hours for 10-14 days 10

HIV-infected patients should receive the same penicillin regimens as HIV-negative patients 11
Pregnant women should be treated with the penicillin regimen appropriate for the stage of syphilis 7, 11
Some experts recommend an additional dose of benzathine penicillin G 2.4 million units IM one week after the initial dose for pregnant women with primary, secondary, or early latent syphilis 11, 10

For primary and secondary syphilis, clinical and serological evaluation should be performed at 6 and 12 months after treatment 7, 8
For latent syphilis, clinical and serological evaluation should be performed at 6, 12, 18, and 24 months after therapy 7, 11
Treatment success is defined as a four-fold (2 dilution) decrease in nontreponemal test titers 7
If clinical symptoms develop or nontreponemal titers rise four-fold, CSF examination should be performed and retreatment administered 11

Failure to determine the stage of syphilis before initiating treatment can lead to inadequate treatment 7, 8
Inadequate follow-up of serological response to treatment can lead to treatment failure 11
Not considering HIV testing for all patients with syphilis can lead to missed opportunities for early diagnosis and treatment 11
Failure to examine CSF in HIV-infected patients with late latent syphilis can lead to missed diagnosis of neurosyphilis 11